ASX - By Stock
|
MSB |
Re:
Back pain trial
|
|
Phaedrus
|
35 |
10K |
6 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
35
|
10K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Pick Today's Price Range Low-High... Just for Fun
|
|
Phaedrus
|
1.3K |
431K |
3 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
1.3K
|
431K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Phaedrus
|
132 |
43K |
11 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
132
|
43K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Phaedrus
|
132 |
43K |
22 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
132
|
43K
|
22
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
417K |
7 |
27/07/24 |
27/07/24 |
ASX - By Stock
|
943
|
417K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
NASDAQ hot!!!
|
|
Phaedrus
|
867 |
399K |
25 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
867
|
399K
|
25
|
|
ASX - By Stock
|
MSB |
Re:
CLBP Trial 2024
|
|
Phaedrus
|
13 |
5.9K |
38 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
13
|
5.9K
|
38
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
12K |
3.9M |
6 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
12K
|
3.9M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
12K |
3.9M |
0 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
12K
|
3.9M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
12K |
3.9M |
4 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
12K
|
3.9M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
once approved
|
|
Phaedrus
|
131 |
59K |
20 |
13/07/24 |
13/07/24 |
ASX - By Stock
|
131
|
59K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
once approved
|
|
Phaedrus
|
131 |
59K |
14 |
13/07/24 |
13/07/24 |
ASX - By Stock
|
131
|
59K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Resubmits BLA with FDA for Ryoncil Approval
|
|
Phaedrus
|
265 |
109K |
5 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
265
|
109K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Phaedrus
|
6.0K |
3.0M |
13 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
6.0K
|
3.0M
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Resubmits BLA with FDA for Ryoncil Approval
|
|
Phaedrus
|
265 |
109K |
6 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
265
|
109K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Resubmits BLA with FDA for Ryoncil Approval
|
|
Phaedrus
|
265 |
109K |
16 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
265
|
109K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Resubmits BLA with FDA for Ryoncil Approval
|
|
Phaedrus
|
265 |
109K |
21 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
265
|
109K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
417K |
2 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
943
|
417K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
417K |
21 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
943
|
417K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Phaedrus
|
6.0K |
3.0M |
4 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
6.0K
|
3.0M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Phaedrus
|
6.0K |
3.0M |
9 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
6.0K
|
3.0M
|
9
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
12K |
3.9M |
24 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
12K
|
3.9M
|
24
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
12K |
3.9M |
6 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
12K
|
3.9M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
453K |
26 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
1.0K
|
453K
|
26
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
86K |
18 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
225
|
86K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
86K |
5 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
225
|
86K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
86K |
2 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
225
|
86K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
86K |
6 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
225
|
86K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
86K |
11 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
225
|
86K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
86K |
2 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
225
|
86K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
453K |
7 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
1.0K
|
453K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
453K |
9 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
1.0K
|
453K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
453K |
8 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
1.0K
|
453K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
453K |
4 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
1.0K
|
453K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
453K |
14 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
1.0K
|
453K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
453K |
15 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
1.0K
|
453K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
12K |
3.9M |
8 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
12K
|
3.9M
|
8
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
12K |
3.9M |
7 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
12K
|
3.9M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
dividend
|
|
Phaedrus
|
8 |
3.2K |
12 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
8
|
3.2K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
86K |
20 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
225
|
86K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
86K |
6 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
225
|
86K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
86K |
22 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
225
|
86K
|
22
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
417K |
16 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
943
|
417K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
86K |
24 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
225
|
86K
|
24
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
86K |
5 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
225
|
86K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
86K |
11 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
225
|
86K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
June 24 - MSB % of portfolio AND + or - %
|
|
Phaedrus
|
88 |
36K |
24 |
08/06/24 |
08/06/24 |
ASX - By Stock
|
88
|
36K
|
24
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Phaedrus
|
6.0K |
3.0M |
14 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
6.0K
|
3.0M
|
14
|
|
ASX - By Stock
|
MSB |
Re:
June 24 - MSB % of portfolio AND + or - %
|
|
Phaedrus
|
88 |
36K |
18 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
88
|
36K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
7.1M |
15 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
18K
|
7.1M
|
15
|
|